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ABSTRACT 
Background: The precise mechanism by which the immune system is adversely affected in cancer patients 
remains poorly understood, but the accumulation of immune suppressive/pro-tumorigenic myeloid-derived 
suppressor cells (MDSCs) is thought to be one prominent mechanism contributing to immunologic tolerance of 
malignant cells in epithelial ovarian cancer (EOC). To this end, we hypothesized genetic variation in MDSC 
pathway genes would be associated with survival after EOC diagnoses. 
Methods: We measured the hazard of death due to EOC within 10 years of diagnosis, overall and by invasive 
subtype, attributable to SNPs in 24 genes relevant in the MDSC pathway in 10,751 women diagnosed with 
invasive EOC. Versatile Gene-based Association study (VEGAS) and the Admixture Likelihood method (AML), 
were used to test gene and pathway associations with survival. 
Results: We did not identify individual SNPs that were significantly associated with survival after correction for 
multiple testing (p<3.5 x 10-5), nor did we identify significant associations between the MDSC pathway overall, 
or the 24 individual genes and EOC survival.  
Conclusions: In this well-powered analysis, we observed no evidence that inherited variations in MDSC-
associated SNPs, individual genes, or the collective genetic pathway contributed to EOC survival outcomes.   
Impact: Common inherited variation in genes relevant to MDSCs were not associated with survival in women 
diagnosed with invasive EOC. 
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INTRODUCTION 
Survival after a diagnosis of epithelial ovarian cancer (EOC) has seen only modest improvements in recent 
decades, making the identification of novel mechanisms and pathways associated with EOC prognosis 
imperative. EOC is associated with immunosuppressive pathways including regulatory T cells and myeloid 
derived suppressor cells (MDSC) that can be barriers to anti-tumor immunity and adversely affect clinical 
outcomes. To this end, MDSCs suppress the antigen-specific T cell response by both CD4+ and CD8+ T cells, 
and elevated concentrations of MDSCs have been detected in the peripheral blood of cancer patients when 
compared with normal controls [1, 2] . We hypothesized that common inherited genetic variation in genes 
involved in the MDSC pathway is associated with survival following ovarian cancer diagnosis. 
 
MATERIALS AND METHODS 
We conducted a pooled analysis utilizing individual-level data from 28 studies in the Ovarian Cancer 
Association Consortium (OCAC) to assess the association of genes in the MDSC associated pathway with 
EOC survival. Participants included 11,034 women aged 18 years and older with a histologically confirmed 
primary diagnosis of invasive EOC, fallopian tube cancer, or primary peritoneal cancer who were genotyped on 
the Ilumina iSelect array designed for the Collaborative Oncological Gene-environment Study (COGS) [3]. 
Clinical, epidemiological, and follow-up data were made available for all analyses. 
To assess the association between invasive EOC outcome and inherited variation in the MDSC pathway, we 
conducted SNP, gene, and pathway-based analyses of 24 candidate genes relevant to the biology of MDSCs, 
as established from an extensive literature review utilizing the PubMed database (ARG1, CD274, CSF2, CSF3, 
EIF2AK4, FLT3, IL10RA, IL13RA2, IL4, IL4R, IL5RA, IL6R, IDO, IRF8, KITLG, MMP1, MMP12, MMP3, MMP9, 
NOS2A, PSME4, STAT1, STAT3, VEGFA). SNP selection and quality control were performed as previously 
described, yielding a total of 736 SNPs for analyses [4]. We calculated the effective number of independent 
SNPs tested; this value was used in a Bonferroni correction to determine single SNP significance [4].  We 
utilized Cox proportional hazards regression models adjusted for age, tumor stage and grade to estimate 
hazard ratios (HRs) and 95% confidence intervals (CIs) representing SNP associations with EOC overall and 
by invasive histotype. Survival time was defined as the time from diagnosis of invasive EOC until death from 
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any cause or time of last follow-up. Analyses accommodated left truncation to account for prevalent cases 
where appropriate and right censoring was done at > 10 years follow-up time.  Analyses and graphics were 
done using R (https://www.r-project.org). Gene- and pathway-based tests of association with hazard of death 
were performed using Versatile Gene-based Association Study (VEGAS) and the Admixture Likelihood Method 
(AML), respectively [5] [6].  
RESULTS 
The clinical characteristics of the study population are presented in Table 1. As expected, the majority of 
patients were diagnosed with serous EOCs, had poorly differentiated tumors, and were diagnosed with distant 
disease.  
We considered p<3.5 x 10-5 as the threshold for significance, based on a Bonferroni correction for the 
estimated number of independent SNPs (n=288) across five histotypes. Single SNP associations for EOC 
overall and by invasive histotype are shown in circular Manhattan style plots in Figure 1 with SNPs showing 
p<0.01 highlighted in red. The most significant single SNP was the C allele of rs6492925 in EIF2AK4 on 
chromosome 15, with a reduction in hazard of death in women with mucinous tumors (HR=0.57, 95% CI= 0.42, 
0.78, p=3.7 x 10-4).  
 The most significant gene-based associations for all invasive ovarian cancer cases (KITLG, p=.07), high-
grade serous (VEGFA, p=.11), mucinous (EIF2AK4, p=.015), endometrioid (CSF, p=.02) and clear cell 
(CD274, p=.037) did not the pass multiple test correction threshold set for testing the 24 genes. Taken together 
the 24 genes showed no significant association with any histotype; mucinous cell tumors showed the most 
significant MDSC pathway association with survival (p=0.11). 
DISCUSSION 
Assuming genotyping captures, on average, 70% of the variation in each gene for tests of association 
with overall EOC and given the proportion of events at 51%, our study had 80% power at p<3.5 x 10-5 to detect 
an HR of 1.11 to 1.24 for minor allele frequencies between 40% and 10%, respectively. We conducted a well-
powered, hypothesis-driven study to evaluate a role for common inherited variation in MDSC pathway genes 
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with EOC survival; we observed no evidence of an association at the SNP, gene or pathway level with EOC 
survival. To date, neither genome wide analyses of single SNP association with progression free survival nor 
copy number variation with overall survival showed significant findings and did not report suggestive 
associations in these genes [7, 8]. It is possible that rare variation in MDSC- associated genes not captured by 
these analyses could be correlated with EOC outcomes or that the magnitude of effect sizes were below 
detection. Additionally, recent work has identified an expanding list of genes associated with MDSCs, thus 
future studies should consider the importance of this emerging knowledge of MDSC biology.   
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Table 1. Clinical characteristics of invasive epithelial ovarian cancer cases from the Ovarian 
Cancer Association Consortium analyzed for association with MSDC genetic variation 
Patient Characteristics 
Vital Status at last follow up  
 Total invasive EOC cases 
N=10,751 Alive N=5243 (48.8%)
Deceased 
N=5508 (51.2%) 
Age at diagnosis 
<50 years 1627 (59.1%) 1125 (40.9%) 2752 
50-69 years 3100 (47.4%) 3445 (52.6%) 6545 
70+ years 516 (35.5%) 938 (64.5%) 1454 
Histology    
Serous 2765 (39.7%) 4207 (60.3%) 6972 
    high grade serous 2210 (38.2%) 3568 (61.8%) 5578 
Mucinous 504 (72.1%) 197 (27.9%) 701 
Endometrioid 1058 (68.7%) 485 (31.3%) 1543 
Clear Cell 529 (67.1%) 260 (32.9%) 789 
Mixed Cell 215 (56.7%) 166 (43.3%) 381 
Undifferentiated/Poorly differentiated 92 (42.6%) 124 (57.4%) 216 
Unknown Epithelial 70 (49.6%) 69 (50.3%) 139 
Grade    
Well Differentiated 757 (70.5%) 316 (29.3%) 1073 
Moderately Differentiated 1107 (50.6%) 1079 (49.4%) 2186 
Poorly differentiated 2185 (42.4%) 2969 (57.6%) 5154 
Undifferentiated 284 (46.8%) 323 (53.2%) 607 
Unknown 583 (58.1%) 419 (41.9%) 1002 
Stage    
Localized 1393 (81.3%) 320 (18.7%) 1713 
Regional 1314 (66.4%) 665 (33.6%) 1979 
Distant 2109 (34.3%) 4034(65.7%) 6134 
Unknown 178 (55.5%) 143 (44.5%) 321 
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Figure legend 
Figure 1. These five concentric circles are circular standard Manhattan plots. The chromosome is on the outer 
circle,  –log10 p-values are on the (vertical) y-axis with each circle representing the p-value from single SNP 
tests of association with overall survival adjusted for age, stage and grade. The Manhattan plots are as follows: 
A) all ovarian cancer cases B) high grade serous  C) mucinous cell D) endometrioid and E) clear cell. The red 
dashed line designates p=.01 , –log10(p-value)=2,  with all red-colored SNPs above that line reflecting SNPs 
p<.01. 
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